shogaol and Obesity

This study investigated the ability of 6-shogaol to reduce obesity in C57BL/6J mice fed with high-fat diet (HFD). After 12 weeks of 6-shogaol (20, 40, 60 mg/kg/2 days) intervention, obesity related indicators, gut microbiota and metabonomics of mice were analyzed. The obesity degree and blood lipid level of mice treated with 6-shogaol were reduced, and glucose homeostasis was improved, especially in mice treated with low-dose. The intervention of 6-shogaol increased the diversity of gut microbiota and decreased the ratio of Firmicutes and Bacteroides. 6-shogaol also led to changes in metabonomics. There were 5, 4 and 6 different metabolites of 6-shogaol at low, medium and high doses. Among them, Solacauline, PE (22:5 (4Z, 7z, 10z, 13z, 13z, 16z)/14:1 (9z)) and presqualene diphosphate have strong correlation with Akkermansia, Brucella, Odoribacter and Mucispirillum. This study aims to provide a theoretical foundation for clarifying the molecular mechanism of 6-shogaol in improving obesity.

Topics: Animals; Diet, High-Fat; Gastrointestinal Microbiome; Metabolomics; Mice; Mice, Inbred C57BL; Obesity

This study explored the anti-obesity effect of 6-shogaol and the underlying mechanisms by using Network pharmacology for the prediction and verification of molecular targets and pathways of 6-shogaol against obesity. Furthermore, the results were verified by molecular docking and cell experiments. A total of 86 core targets of 6-shogaol towards obesity were identified. Among them, AKT1 and PIK3CA were confirmed by using the molecular docking. In 3T3-L1 preadipocyte model, 6-shogaol significantly inhibited proliferation and differentiation, reducing the accumulation of lipid droplets. Compared with the control group, the inhibition rates of 6-shogaol on TG and TC were 90.8% and 40.0%, respectively. Additionally, 6-shogaol down-regulated the expression of PPAR-γ and C/EBP-α, while it decreased the phosphorylation of IRS-1, PI3K and AKT. This study, for the first time, confirmed the effect of 6-shogaol on improving obesity through PI3K/AKT pathway. An anti-obesity bioactivity study was further recommended for the development of novel anti-obesity products.

Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Catechols; Mice; Molecular Docking Simulation; Network Pharmacology; Obesity; Phosphatidylinositol 3-Kinases

Dementia is a progressive cognitive diminution impeding with normal daily activities that is constantly on the increase. Currently, the estimated prevalence is 50 million affected people worldwide, a figure expected to triple within the next 30 years. While the pathophysiology of the different types of dementia is complex, likely involving the interplay between multiple genetic and environmental factors, strong evidence points towards an important link between diet and cognitive health. Here we examined the consequences of high-fat, high-sugar Western diet (HFSD)-induced obesity on cognitive performance in the fear conditioning task in mice and explored a possible beneficial effect of 6-shogaol (6S), an active constituent of ginger, in this model. Chronic exposure to HFSD significantly enhanced body weight gain in C57BL/6N mice and this effect was prevented by treatment with 6S. HFSD + vehicle-treated mice presented with a selective deficit in cued fear memory, which was not observed in HFSD + 6S-treated animals. The findings of this study provide first evidence for a beneficial effect of 6S on HFSD-induced obesity and emotional memory deficit in mice.

Topics: Animals; Behavior, Animal; Catechols; Cognitive Dysfunction; Conditioning, Classical; Cues; Diet, Western; Fear; Male; Memory; Mice; Mice, Inbred C57BL; Nootropic Agents; Obesity

Grains of paradise (GP) is the seed of Aframomum melegueta, which is widely distributed throughout West Africa and has been used as a spice and a folk remedy for a long time. Anti-obesity effect of GP intake was demonstrated in a previous report. Aim of the present study was to isolate some compounds in GP and clarify the anti-obesity mechanism.. Ten vanilloid compounds were isolated. Among them, 1-(4'-hydroxy-3'-methoxyphenyl)-decan-3-ol and 1-(4'-hydroxy-3'-methoxyphenyl)-3-octen-5-one were determined as novel compounds and 6-gingerol, 6-paradol and 6-shogaol were identified as the major constituents in GP extract. Moreover, the extract and 6-gingerol, which is one of the principal components of GP extract, were orally administered to rats to investigate the effect on sympathetic nerve activity (SNA) in brown adipose tissue (BAT). The injection of GP extract and 6-gingerol decreased BAT-SNA, whereas capsaicin, which is a major component of chili pepper, activates the sympathetic nervous system.. This study suggested that GP extract and 6-gingerol were largely unrelated to the anti-obesity effect by the activation of interscapular BAT-SNA and had a different anti-obesity mechanism to capsaicin. © 2018 Society of Chemical Industry.

Topics: Adipose Tissue, Brown; Animals; Catechols; Fatty Alcohols; Guaiacol; Humans; Ketones; Molecular Structure; Obesity; Plant Extracts; Rats; Seeds; Sympathetic Nervous System; Zingiberaceae